Acording to an article printed in Clinical Chemistry and Laboratory Medicine an evaluation of The NGAL Test on the Beckman Coulter AU 5822 has been carried out.
A comparison of the results was then made with the ARCHITECT NGAL test from Abbott,
Lets skip to the result. It works just fine, or as the article puts it: “Conclusions: This analytical evaluation attests that the NGAL Test™ has several technical and analytical advantages, including no manual pretreatment, low volume of sample (i.e., 3 μL), fast turnaround time (approx. 10 min), low imprecision, wide dynamic range, optimal linearity.”
But thats old news to the Bioporto beliver,
What does the article tells us besides that?
Well, it states that the test has been made on the brand new AU5800 series, the fastes AU ever. Currently sold in 50 examples in Europe and Asia, and just recently launced on the US marked. (It’s capable of running between 2.000 and 10.000 test pr hour) Its saying something about the intended use of the test.
And I have to say I love the short and clear statement: “Background: The neutrophil gelatinase associated lipocalin (NGAL) has been identified as the most promising biomarker of acute kidney injury (AKI). This study was aimed to evaluate a NGAL immunoassay on Beckman Coulter AU 5822.”
No need to wrap it in.
[…] relation to the former post, stating that an evaluation of the The NGAL Test on BC 5822, had been carried out, the full text of […]
[…] relation to the former post, stating that an evaluation of the TNT on BC 5822, had been carried out, the full text is now […]